Please login to the form below

Not currently logged in
Email:
Password:

Medifacts announces USD 6.2m study award

Medifacts International, a US-based provider of non-invasive cardiac safety services, signs a four-year global study worth approximately USD 6.2m

Medifacts International, a US-based provider of non-invasive cardiac safety services, has signed a four-year global study worth approximately USD 6.2m.

The study is a late state registration programme sponsored by a major, but presently unnamed, biotechnology company.

Medifacts will provide comprehensive support for ECG, Holter, as well as ABPM endpoints including provision of equipment for digital collection of cardiac safety data that will be transferred to Medifacts for processing and analysis.

The company will use its proprietary web-based platform, WebHeart, which will enable efficient management of the data and provide a fully-digital environment for manual measurement and overread of ECGs and other cardiac safety and efficacy data while exceeding regulatory guidance and technical standards.

Michael Woehler, Medifacts' CEO, said: "The award represents an endorsement of the tremendous quality of our global services and a continuing vote of long-term confidence in the company by the sponsor community. Our WebHeart platform continues to set the global standard in cardiac safety data collection, management and submission, and we continue to consolidate our position as one of the top five global cardiac safety businesses.î

27th September 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...
Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...

Infographics